Genmab's Executive VP and CFO to retire in 2020
Published on 31/10/19 at 10:43am
David Eatwell, Executive Vice President and Chief Financial Officer at Genmab, has announced his intention to step down from the role next year, with a proposed leaving date of 29 February 2020.
Eatwell has been with the company for 11 years, joining in 2008 as its Chief Financial Officer. He will be succeeded by Anthony Pagano, currently Senior Vice President Finance and Corporate Development at the company, who originally joined in 2007 and was promoted to Senior Vice President in 2011.
Eatwell’s exit date of February allows him to stay in the role until his responsibilities can be safely transitioned over to Pagano.
“David has been instrumental in helping build Genmab into the antibody innovation powerhouse that it is today,” commented Dr Jan van de Winkel, Chief Executive Officer of Genmab. “With David’s leadership and financial stewardship, we were able to weather some challenging years and enter transformative collaboration agreements with Janssen, GSK and Novartis. On behalf of the Genmab team, I wish David and his family the very best for the future.”
The company also revealed alongside the announcement that it will look to introduce a fourth position for an Executive Vice President and Chief Operating Officer, with a management remit covering commercial, business development and information technology functions at the company.
Matt Fellows
- Login or register to post comments
- Printer-friendly version
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
Related content
- AbbVie and Genmab sign drug development and commercialisation deal worth up to $4bn
- Genmab announces newly-created Chief Financial Officer appointment
- Ipsen appoints new Exec VP and Chief Medical Officer
- Genmab's Darzalex secures CHMP recommendation in Europe for front-line multiple myeloma
- European Commission approves Genmab's Darzalex combo in newly diagnosed multiple myeloma
Comments
It's a nice article. In this article, the author explains about Eatwell, He is a Genmab's Executive VP and CFO to retire in 2020. hostsailor First time I read an article about him. I suggest to all are please read this article.
The company has announced that Executive VP and CFO, Jesper Hansen will retire on December 31, 2020. You can click here https://bestonlinewritingservice.com/resume-writing-services/ for educational help too as according to Genmab's statement, his retirement comes as a consequence of the fact that it takes time for a successor in this function and in order to avoid unnecessary disruptions in the middle of critical steps in its development path.